Fig. 3.

Systemic administration of the CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) rapidly blocks the hyperphagic effect of TP. Bars represent means and vertical lines 1 SE of the energy intake measured in animals at 1, 2, and 4 h after treatment with TP (400 μg sc) and/or AM251 (3 mg/kg sc) or their respective vehicles. #Values from TP-treated animals that are significantly different (P < 0.05, multifactorial ANOVA/LSD; n = 4–6) from vehicle-treated controls; *Values from AM251-treated animals that are significantly different (P < 0.05, multifactorial ANOVA/LSD; n = 4–6) from those from their vehicle-treated counterparts.